Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: Analysis of 108 patients

被引:285
作者
Thieblemont, C
Bastion, Y
Berger, F
Rieux, C
Salles, G
Dumontet, C
Felman, P
Coiffier, B
机构
[1] CTR HOSP LYON SUD,SERV HEMATOL,F-69465 PIERRE BENITE,FRANCE
[2] CTR HOSP LYON SUD,HEMATOL LAB,F-69465 PIERRE BENITE,FRANCE
[3] HOP EDOUARD HERRIOT,SERV ANAT PATOL,LYON,FRANCE
关键词
D O I
10.1200/JCO.1997.15.4.1624
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Characteristics and outcome of 108 patients with mucosa-associated lymphoid tissue (MALT) lymphoma were analyzed according to initial location of the lymphoma, within or outside of the gastrointestinal (GI) tract. Patients and Methods: One hundred eight patients with MALT lymphoma were studied. Fifty-five patients (51%) had GI involvement and 53 patients (49%) had another involved extranodal site: 13 orbit; 11 lung; 10 skin; seven parotid; six thyroid; three Waldeyer's ring; two breast; and one pancreas involvement, At diagnosis, 47 patients (44%) had stage IE, 26 (24%) had stage IIE, and 35 (32%) herd disseminated disease. No significant difference in the clinical or biologic characteristics was observed between GI and non-GI patients. Results: Complete response after the first treatment was reached in 76% of the patients, with no difference between the two subgroups. With a median follow-up of 52 months, median survival was not reached and was identical in the two subgroups, but GI MALT patients had a longer time to progression (8.9 years compared with 4.9 years in non-GI patients; P = .01), The different non-GI locations seemed to have a similar outcome, Conclusion: MALT lymphoma is an indolent disease that usually presents as localized extranodal tumor without accompanying adverse prognostic factor, and these patients have a good outcome, However, non-GI patients seem to progress more often than GI patients. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:1624 / 1630
页数:7
相关论文
共 38 条
[1]   PRIMARY PULMONARY LYMPHOMA - A RE-APPRAISAL OF ITS HISTOGENESIS AND ITS RELATIONSHIP TO PSEUDOLYMPHOMA AND LYMPHOID INTERSTITIAL PNEUMONIA [J].
ADDIS, BJ ;
HYJEK, E ;
ISAACSON, PG .
HISTOPATHOLOGY, 1988, 13 (01) :1-17
[2]   REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION [J].
BAYERDORFFER, E ;
NEUBAUER, A ;
RUDOLPH, B ;
THIEDE, C ;
LEHN, N ;
EIDT, S ;
STOLTE, M .
LANCET, 1995, 345 (8965) :1591-1594
[3]   NONFOLLICULAR SMALL B-CELL LYMPHOMAS - A HETEROGENEOUS GROUP OF PATIENTS WITH DISTINCT CLINICAL-FEATURES AND OUTCOME [J].
BERGER, F ;
FELMAN, P ;
SONET, A ;
SALLES, G ;
BASTION, Y ;
BRYON, PA ;
COIFFIER, B .
BLOOD, 1994, 83 (10) :2829-2835
[4]   PRIMARY B-CELL GASTRIC LYMPHOMA - A CLINICOPATHOLOGICAL STUDY OF 145 PATIENTS [J].
COGLIATTI, SB ;
SCHMID, U ;
SCHUMACHER, U ;
ECKERT, F ;
HANSMANN, ML ;
HEDDERICH, J ;
TAKAHASHI, H ;
LENNERT, K .
GASTROENTEROLOGY, 1991, 101 (05) :1159-1170
[5]   PROGNOSTIC FACTORS IN AGGRESSIVE MALIGNANT-LYMPHOMAS - DESCRIPTION AND VALIDATION OF A PROGNOSTIC INDEX THAT COULD IDENTIFY PATIENTS REQUIRING A MORE INTENSIVE THERAPY [J].
COIFFIER, B ;
GISSELBRECHT, C ;
VOSE, JM ;
TILLY, H ;
HERBRECHT, R ;
BOSLY, A ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :211-219
[6]  
COIFFIER B, 1993, SEMIN ONCOL, V20, P89
[7]   14 YEARS OF HIGH-DOSE CHOP (ACVB REGIMEN) - PRELIMINARY CONCLUSIONS ABOUT THE TREATMENT OF AGGRESSIVE-LYMPHOMA PATIENTS [J].
COIFFIER, B .
ANNALS OF ONCOLOGY, 1995, 6 (03) :211-217
[8]   PRIMARY PULMONARY LYMPHOMAS - A CLINICAL-STUDY OF 70 CASES IN NONIMMUNOCOMPROMISED PATIENTS [J].
CORDIER, JF ;
CHAILLEUX, E ;
LAUQUE, D ;
REYNAUDGAUBERT, M ;
DIETEMANNMOLARD, A ;
DALPHIN, JC ;
BLANCJOUVAN, F ;
LOIRE, R .
CHEST, 1993, 103 (01) :201-208
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   EFFICACY OF SINGLE-AGENT CHEMOTHERAPY IN LOW-GRADE B-CELL MUCOSA-ASSOCIATED LYMPHOID-TISSUE LYMPHOMA WITH PROMINENT GASTRIC EXPRESSION [J].
HAMMEL, P ;
HAIOUN, C ;
CHAUMETTE, MT ;
GAULARD, P ;
DIVINE, M ;
REYES, F ;
DELCHIER, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2524-2529